Clinical trials: Recurrent Hepatocellular Cancer
Hepatocellular Carcinoma
Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan.
- Trial name
- NCT06354387
- Testing
- Alectinib (Alecensa), Nivolumab (Opdivo)
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- China Medical University Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Selumetinib in Treating Patients With Locally Advanced or Metastatic Liver Cancer
This phase II trial is studying selumetinib to see how well it works in treating patients with locally advanced or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00604721
- Testing
- selumetinib, pharmacological study
- Where
- 6 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Carcinoma, Beyond Milan Criteria
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
Surgical resection is the primary curative treatment for patients with hepatocellular carcinoma (HCC), with a 5-year overall survival rate of 60-80% post-surgery.
- Trial name
- NCT06467799
- Testing
- Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1
- Where
- China
- Volunteers
- 39 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00427973
- Testing
- cediranib maleate, laboratory biomarker analysis, computed tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer
CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with advanced or metastatic cholangiocarcinoma that cannot be removed by surgery.
- Conditions
- Adult Primary Cholangiocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Extrahepatic Bile Duct, Cholangiocarcinoma of the Gallbladder
- Trial name
- NCT01766219
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Wake Forest University Health Sciences
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer
Lapatinib ditosylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well lapatinib ditosylate works in treating patients with unresectable liver or…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00107536
- Testing
- lapatinib ditosylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Hepatocellular Carcinoma
Pringle's Maneuver Versus Selective Hepatic Vascular Exclusion in Hepatectomy
To confirm that SHVE is a safe and effective procedure and it can prevent bleeding of the hepatic vein. To evaluate the recurrence and metastasis in HCC patients undergoing hepatectomy by SHVE.To evaluate that SHVE can improve…
- Trial name
- SHVE (NCT00820339)
- Testing
- Selective Hepatic Vascular Exclusion, Pringle's Maneuver
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Hepatocellular Carcinoma
Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu…
- Trial name
- YYFZJDTRHCLT3D (NCT04264962)
- Testing
- Yang Yin Fu Zheng Jie Du therapy, Routine medical care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Beijing Ditan Hospital
Hepatocellular Carcinoma
Laparoscopic Surgery Versus Radiofrequency Ablation for Recurrent HCC
Hepatocellular carcinoma (HCC) is the fifth most common and the third leading cause of death from cancer worldwide1 . Hepatectomy is still the main effective treatment for HCC accompanying with well-preserved cirrhosis when liver…
- Trial name
- NCT02535117
- Testing
- Laparoscopic Surgery(LS), RFA
- Volunteers
- 216 people
- Sponsor
- Sun Yat-sen University
Hepato Cellular Carcinoma (HCC), Liver Resection
Retrospective Clinical Validation of HepatoPredict
HepatoPredict is an innovative prognostic tool to support hepatologists, hepatobiliary surgeons and multidisciplinary teams in deciding on the best therapeutical approach for a patient with Hepatocellular Carcinoma, the most…
- Conditions
- Hepato Cellular Carcinoma (HCC), Liver Resection, Liver Transplantation
- Trial name
- NCT06894524
- Volunteers
- 200 people
- Sponsor
- Ophiomics
Hepatocellular Carcinoma, Scirrhous, Recurrence Tumor
HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma
Liver transplant is the most effective treatment for hepatocellular carcinoma (HCC) in cirrhosis. Due to organs shortage, the proper selection of patients is imperative.
- Trial name
- HepatoPredict (NCT04499833)
- Testing
- liver transplant
- Where
- Portugal
- Volunteers
- 40 people
- Sponsor
- Centro Hospitalar de Lisboa Central
Hepatocellular Carcinoma
A Trial of Licartin for Preventing Tumor Recurrence After Liver Resection
The aim of this study is to analyze the therapeutic effect of adjuvant Licartin therapy after resection.Patients receiving curative resection (R0) were randomized to postoperative Licartin group and no Licartin group.
- Trial name
- NCT00819650
- Testing
- Licartin (generic name,[131I]metuximab injection)
- Where
- China
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
HCC
A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for Recurrence
For patients with early- to mid-stage hepatocellular carcinoma (HCC), the five-year postoperative recurrence and metastasis rate remains as high as 70%, significantly impacting patient prognosis.Therefore, perioperative therapy…
- Trial name
- NCT07009470
- Testing
- Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar), TACE
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Tongji Hospital
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Doxorubicin and Bortezomib in Treating Patients With Liver Cancer
This phase II trial is studying how well giving doxorubicin together with bortezomib works in treating patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00083226
- Testing
- doxorubicin, bortezomib
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Hepatocellular Cancer
Major RF Ablations of Hepatomas Under MR Thermometry Monitoring
Object of the study: To assess the effectiveness of MR temperature monitoring of RFA of large hepatocellular carcinomas (HCC) (≥ 5 cm) in terms of complete tumor necrosis rate achieved and in term of reduction of the number of…
- Trial name
- ARMTICH (NCT01486134)
- Testing
- Multipolar Radiofrequency ablation
- Where
- France
- Volunteers
- 15 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
- Trial name
- ATHENA (NCT06084884)
- Testing
- AZD5851
- Where
- 19 sites in United States, Japan and 1 more
- Volunteers
- 94 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma Recurrent
A Study of Laparoscopic Hepatectomy Versus RFA in the Treatment of Recurrent HCC
To observe and compare the short-term and long-term oncological outcome of laparoscopic hepatectomy and radiofrequency ablation in the treatment of recurrent hepatocellular carcinoma .
- Trial name
- NCT03313648
- Testing
- Laparoscopic Hepatectomy, Radiofrequency Ablation
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Southwest Hospital, China
Colorectal Cancer, Metastatic Cancer
Isolated Hepatic Perfusion With Melphalan Followed by Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
RATIONALE: Drugs used in chemotherapy, such as melphalan, leucovorin, oxaliplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00103298
- Testing
- FOLFOX regimen, fluorouracil, isolated perfusion
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Recurrent or Metastatic Solid Tumors
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma…
- Trial name
- NCT06330064
- Testing
- Ifinatamab deruxtecan
- Where
- 120 sites in United States, Argentina and 16 more
- Volunteers
- 680 people
- Sponsor
- Daiichi Sankyo